BeiGene Net Income 2014-2024 | ONC
BeiGene annual/quarterly net income history and growth rate from 2014 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- BeiGene net income for the quarter ending September 30, 2024 was $-0.121B, a 156.33% decline year-over-year.
- BeiGene net income for the twelve months ending September 30, 2024 was $-0.860B, a 10.32% decline year-over-year.
- BeiGene annual net income for 2023 was $-0.882B, a 56% decline from 2022.
- BeiGene annual net income for 2022 was $-2.004B, a 37.45% increase from 2021.
- BeiGene annual net income for 2021 was $-1.458B, a 8.71% decline from 2020.
BeiGene Annual Net Income
(Millions of US $) |
| 2023 |
$-882 |
| 2022 |
$-2,004 |
| 2021 |
$-1,458 |
| 2020 |
$-1,597 |
| 2019 |
$-949 |
| 2018 |
$-674 |
| 2017 |
$-93 |
| 2016 |
$-119 |
| 2015 |
$-57 |
| 2014 |
$-18 |
| 2013 |
$-7 |
BeiGene Quarterly Net Income
(Millions of US $) |
| 2024-09-30 |
$-121 |
| 2024-06-30 |
$-120 |
| 2024-03-31 |
$-251 |
| 2023-12-31 |
$-368 |
| 2023-09-30 |
$215 |
| 2023-06-30 |
$-381 |
| 2023-03-31 |
$-348 |
| 2022-12-31 |
$-445 |
| 2022-09-30 |
$-558 |
| 2022-06-30 |
$-566 |
| 2022-03-31 |
$-435 |
| 2021-12-31 |
$-606 |
| 2021-09-30 |
$-438 |
| 2021-06-30 |
$-480 |
| 2021-03-31 |
$66 |
| 2020-12-31 |
$-473 |
| 2020-09-30 |
$-425 |
| 2020-06-30 |
$-335 |
| 2020-03-31 |
$-364 |
| 2019-12-31 |
$-388 |
| 2019-09-30 |
$-307 |
| 2019-06-30 |
$-86 |
| 2019-03-31 |
$-168 |
| 2018-12-31 |
$-268 |
| 2018-09-30 |
$-144 |
| 2018-06-30 |
$-157 |
| 2018-03-31 |
$-105 |
| 2017-12-31 |
$-99 |
| 2017-09-30 |
$117 |
| 2017-06-30 |
$-61 |
| 2017-03-31 |
$-51 |
| 2016-12-31 |
$-38 |
| 2016-09-30 |
$-35 |
| 2016-06-30 |
$-24 |
| 2016-03-31 |
$-22 |
| 2015-12-31 |
$-27 |
| 2015-09-30 |
|
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-10 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
